Role of SGLT2 Inhibitors, DPP-4 Inhibitors, and Metformin in Pancreatic Cancer Prevention

Tooba Laeeq,Maheen Ahmed,Hina Sattar,Muhammad Hamayl Zeeshan,Meher Binte Ali

DOI: https://doi.org/10.3390/cancers16071325

2024-03-29

Cancers

Abstract:Pancreatic carcinoma is a highly aggressive tumor that usually presents when it has already metastasized. Therapeutic options for cure remain scarce and rely on combination chemotherapy with limited sustainability. Diabetes is considered an important risk factor for the development of pancreatic cancer due to the production of proinflammatory cytokines, which result in increased cell proliferation. More than half of patients diagnosed with pancreatic cancer eventually develop diabetes due to the destruction of insulin-producing cells. The interlinkage of both diseases might identify a possible preventative strategy for reducing the incidence of pancreatic carcinoma. This study reviewed the recent literature on the association between pancreatic cancer risk and SGLT2 inhibitors, GLP-1 RA, DPP-4 inhibitors, and biguanides. There are mixed data regarding the relationship between GLP-1 RA and DPP-4 inhibitors and pancreatic cancer, with some trials suggesting that they might increase the risk. In contrast, studies have mostly revealed that SGLT2 inhibitors have an antiproliferative effect on various tumors, such as liver, pancreatic, prostate, bowel, lung, and breast carcinoma, which might be due to their mechanism of blockage of reabsorption of glucose by cells, lowering the amount of available glucose for the growth of tumor cells. Metformin, the first-line agent for diabetes, has also been shown to be associated with decreasing pancreatic cancer risk and improving prognosis in those who already have the disease. Dedicated trials are needed to further delineate the association of antidiabetic drugs with the risk of pancreatic cancer in the general population, as previous studies have mostly focused on diabetic patients.

oncology

What problem does this paper attempt to address?

This paper attempts to explore the roles of SGLT2 inhibitors, DPP - 4 inhibitors and metformin in the prevention of pancreatic cancer. Specifically, the paper mainly focuses on how these antidiabetic drugs affect the risk of pancreatic cancer through different mechanisms, and evaluates their immunomodulatory effects, safety and the association with pancreatic cancer.

### Main problems:
1. **High risk of pancreatic cancer**: Pancreatic cancer is a highly malignant tumor and is usually detected when metastasis has already occurred. Treatment options are limited and mainly rely on combination chemotherapy, with limited effectiveness persistence.
2. **The relationship between diabetes and pancreatic cancer**: Diabetes is considered an important risk factor for pancreatic cancer because hyperglycemia and high insulin levels promote cell proliferation. In addition, more than half of pancreatic cancer patients will eventually develop diabetes, which may be due to islet cell damage.
3. **The roles of antidiabetic drugs**:
- **SGLT2 inhibitors**: By blocking glucose reabsorption, they reduce the intracellular glucose supply, thereby inhibiting tumor growth.
- **DPP - 4 inhibitors**: By inhibiting the activity of DPP - 4 enzyme, they prolong the half - lives of GLP - 1 and GIP, but their impact on pancreatic cancer is controversial.
- **Metformin**: By inhibiting gluconeogenesis in the liver, it reduces the risk of pancreatic cancer and improves the prognosis of patients with pancreatic cancer.

### Research purposes:
- **To evaluate the potential roles of SGLT2 inhibitors, DPP - 4 inhibitors and metformin in the prevention of pancreatic cancer**.
- **To analyze the immunomodulatory effects and safety of these drugs**.
- **To explore the relationship between these drugs and the risk of pancreatic cancer**, and provide directions for further research.

### Conclusions:
- **SGLT2 inhibitors**: Multiple studies have shown that SGLT2 inhibitors have antitumor effects and can reduce the risk of pancreatic cancer.
- **DPP - 4 inhibitors**: There are mixed data regarding the relationship between DPP - 4 inhibitors and the risk of pancreatic cancer. Some studies suggest that they may increase the risk, while other studies have not found a significant association.
- **Metformin**: Multiple studies have shown that metformin can reduce the risk of pancreatic cancer and improve the prognosis of patients with pancreatic cancer.

In summary, this paper aims to explore the potential roles and mechanisms of these antidiabetic drugs in the prevention of pancreatic cancer by synthesizing existing literature, and provide references for future research and clinical applications.